Literature DB >> 17334642

Association of total plasma homocysteine with methylenetetrahydrofolate reductase genotypes 677C>T, 1298A>C, and 1793G>A and the corresponding haplotypes in Swedish children and adolescents.

Anna K Böttiger1, Anita Hurtig-Wennlöf, Michael Sjöström, Agneta Yngve, Torbjörn K Nilsson.   

Abstract

We studied 692 Swedish children and adolescents (aged 9-10 or 15-16 years, respectively), in order to evaluate the effect of the methylenetetrahydrofolate reductase (MTHFR) 677C>T, 1298A>C, and 1793G>A polymorphisms on total plasma homocysteine concentrations (tHcy). Genotyping was performed with Pyrosequencing technology. The MTHFR 677C>T polymorphism was associated with increased tHcy concentrations in both the children and the adolescents (P<0.001 for both age groups) in both genders. The effect of MTHFR 1298A>C was studied separately in subjects with the 677CC and 677CT genotypes, and the 1298C allele was found to be associated with higher tHcy levels both when children were stratified according to 677C>T genotypes, and when using haplotype analyses and diplotype reconstructions. The 1793A allele was in complete linkage disequilibrium with the 1298C allele. It was still possible to show that the 1793A allele was associated with lower tHcy levels, statistically significant in the adolescents. In conclusion, a haplotype-based approach was slightly superior in explaining the genetic interaction on tHcy plasma levels in children and adolescents than a simple genotype based approach (R2 adj 0.44 vs. 0.40). The major genetic impact on tHcy concentrations is attributable to the MTHFR 677C>T polymorphism. The common 1298A>C polymorphism had a minor elevating effect on tHcy, whereas the 1793G>A polymorphism had a lowering effect on tHcy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17334642

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  10 in total

1.  Hyperhomocysteinemia is an independent predictor of sub-clinical carotid vascular damage in subjects with grade-1 hypertension.

Authors:  Alberto Mazza; Stefano Cuppini; Laura Schiavon; Marco Zuin; Roberta Ravenni; Giulia Balbi; Domenico Montemurro; Giuseppe Opocher; Maria Rosa Pelizzo; Patrick M Colletti; Domenico Rubello
Journal:  Endocrine       Date:  2013-10-03       Impact factor: 3.633

2.  Methylenetetrahydrofolate reductase ( MTHFR) C677T, A1298C and G1793A genotypes, and the relationship between maternal folate intake, tibia lead and infant size at birth.

Authors:  Katarzyna Kordas; Adrienne S Ettinger; Héctor Lamadrid-Figueroa; Martha M Tellez-Rojo; Mauricio Hérnandez-Avila; Howard Hu; Robert O Wright
Journal:  Br J Nutr       Date:  2009-04-02       Impact factor: 3.718

3.  Association of blood lead levels with methylenetetrahydrofolate reductase polymorphisms among Chinese pregnant women in Wuhan city.

Authors:  Wei Shen; Bin Zhang; Shuyun Liu; Hongling Wu; Xue Gu; Lingzhi Qin; Ping Tian; Yun Zeng; Linxiang Ye; Zemin Ni; Qi Wang
Journal:  PLoS One       Date:  2015-02-27       Impact factor: 3.240

4.  Dysregulated Choline, Methionine, and Aromatic Amino Acid Metabolism in Patients with Wilson Disease: Exploratory Metabolomic Profiling and Implications for Hepatic and Neurologic Phenotypes.

Authors:  Tagreed A Mazi; Gaurav V Sarode; Anna Czlonkowska; Tomasz Litwin; Kyoungmi Kim; Noreene M Shibata; Valentina Medici
Journal:  Int J Mol Sci       Date:  2019-11-26       Impact factor: 5.923

Review 5.  Folic Acid and Homocysteine in Chronic Kidney Disease and Cardiovascular Disease Progression: Which Comes First?

Authors:  Giuseppe Cianciolo; Antonio De Pascalis; Luca Di Lullo; Claudio Ronco; Chiara Zannini; Gaetano La Manna
Journal:  Cardiorenal Med       Date:  2017-06-21       Impact factor: 2.041

6.  Investigation of homocysteine-pathway-related variants in essential hypertension.

Authors:  Javed Y Fowdar; Marta V Lason; Attila L Szvetko; Rodney A Lea; Lyn R Griffiths
Journal:  Int J Hypertens       Date:  2012-10-23       Impact factor: 2.420

7.  Genetic variability & chemotoxicity of 5-fluorouracil & cisplatin in head & neck cancer patients: a preliminary study.

Authors:  Dipali Dhawan; Harsha Panchal; Shilin Shukla; Harish Padh
Journal:  Indian J Med Res       Date:  2013-01       Impact factor: 2.375

8.  A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients.

Authors:  Susanne Blank; Sivaramakrishna Rachakonda; Gisela Keller; Wilko Weichert; Florian Lordick; Rupert Langer; Christoph Springfeld; Thomas Bruckner; Karen Becker; Rajiv Kumar; Katja Ott
Journal:  BMC Cancer       Date:  2014-02-03       Impact factor: 4.430

9.  The effects of genomic polymorphisms in one-carbon metabolism pathways on survival of gastric cancer patients received fluorouracil-based adjuvant therapy.

Authors:  Tingting Zhao; Zhi Xu; Dongying Gu; Peng Wu; Xinying Huo; Xiaowei Wei; Yongfei Tang; Weida Gong; Ming-Liang He; Jinfei Chen
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379

10.  MTHFR variant is associated with high-dose methotrexate-induced toxicity in the Chinese osteosarcoma patients.

Authors:  Leilei Xu; Lujun Wang; Bingchuan Xue; Shoufeng Wang
Journal:  J Bone Oncol       Date:  2018-11-01       Impact factor: 4.072

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.